Case Report

Ayurveda panchakarma treatment success in a case of chronic spontaneous urticaria non-responding to conventional medicine—A case study

Krishna Rao S a, *, A.K. Panda a, Binitha P a, Bikash Ranjan Kar b, Indu S a

a Central Ayurveda Research Institute for Hepatobiliary Disorders, Bhubaneswar, Odisha, India
b Dept of Dermatology Venereology and Leprosy (DVL), IMS & SH, Bhubaneswar, Odisha, India

A R T I C L E   I N F O
Article history:
Received 23 August 2019
Received in revised form
23 January 2022
Accepted 23 January 2022
Available online xxx

Keywords:
Case report
Panchakarma
Chronic spontaneous urticaria
Omalizumab
UAS7 score
Ayurveda

A B S T R A C T
This is a case study of a 34-year-old male patient of Chronic Spontaneous Urticaria (CSU) with severe generalised itching and rashes all over the body since 17 years. The patient has no significant relief with conventional antihistamine therapies, AST (Autologous serum therapy) and Omalizumab (OMA). He was clinically assessed and managed with Ayurvedic Panchakarma procedures like Snehapan (therapeutic administration of unctuous formulation like ghee, oil), Vamana, Virechana and internal medication in line of Seethapitta Chikitsa. The patient was asked to monitor hives and itching daily for one week using a validated weekly Urticaria Activity Score (UAS7) at the baseline, after Vamana, after Virechana and after follow up. The Quality of life was assessed at the baseline and after follow up using Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL). The assessment showed complete remission in disease activity and improvement in Quality of life as per the scores. The hematological and biochemical investigations reflect the safety and efficacy of Ayurveda in management of CSU. © 2022 The Authors. Published by Elsevier B.V. on behalf of Institute of Transdisciplinary Health Sciences and Technology and World Ayurveda Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Chronic spontaneous urticaria (CSU) is defined as the spontaneous recurrent episodes of wheals (hives), angioedema, or both, occurring at least twice a week lasting for six weeks or more with no specific known trigger [1]. The exact incidence and prevalence of chronic urticaria are not known, although it occurs in at least 0.1% and possibly up to 3% of the population, females are more commonly affected than males. Unpredictability and severity of attacks, reduced sleep quality due to itching and associated fatigue negatively affects overall quality of life (QoL). At present second-generation nonsedating H1-antihistamines are used as the first-line treatment for CSU. In nonresponding cases, the treatment options including steroids, AST (Autologous serum therapy), modern biologics such as Omalizumab are used [2].

OMA is a recombinant, humanized, a monoclonal antibody against human immunoglobulin E (IgE) for the treatment of urticaria in patients who do not sufficiently respond to standard therapy [3,4]. Urticaria Activity Score (UAS 7) is a widely accepted and validated easy-to-use tool to help patients quantify urticaria and itching on a daily basis [5]. CSU can be annoying and debilitating to the extent that it interferes with subjective well-being and daily life. So a disease-specific scale to assess Quality of life i.e. Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) is used to assess the impact of CSU [6].

The symptomatology and causative factors of CSU can be compared with the spectrum of Sheethapitta-Udarda-Kotha described in classic Ayurvedic texts [7]. It is a spectrum involving all the three Doshas in the pathogenesis with the predominance of Pitta with Vayu (the combination of two bodily humours) along with Rakthadhathu and Rasadhathu (two affected body tissues) as the main Dushyas. Sheethapitta (a types of allergic condition similar to urticaria) is a Vata predominant condition while Udarda is a Kapha dominant one. Various conditions like Asatmya Ahara (unwholesome food), Virudhahara (incompatible food), and Dushivisha (a type of internal toxin)are common etiological factors for these diseases which can be correlated
with various allergic conditions [8]. In Ayurveda, this condition is primarily managed at the outpatient level with oral medications and in case of nonresponding cases, it is managed as an inpatient by administering suitable Panchakarma (five biopurification procedures) depending upon the severity, chronicity, patient strength, basic constitution, etc. Panchakarma therapy reduces the time of treatment, drug consumption, expenses and improves the quality of life associated with chronic diseases such as skin diseases [9].

2. Patient information

2.1. Presenting complaints

A 34-year-old married, non-smoking, non-alcoholic male patient was presented to OPD (Out-patient department of Central Ayurveda Research Institute for hepatobiliary disorders) (1665/2019) with complaints of severe itching with reddish rashes lasting for 3–4 days, in all parts of the body (Fig. 1a–d). The patient reported that the rashes usually aggravates during the hot climates since 17 years.

2.2. Past medical history

The case was non-responsive to antihistamine therapies, Autologous serum therapy (AST) and OMA. He continued to develop severe itching almost daily. The past medical history of the patients was suggestive of CSU (Table 1).

2.3. Investigations

On examination, the Blood pressure was found to be 100/70 mmHg. Hematological investigations were conducted on April 3, 2019, that revealed hemoglobin (Hb) 15.1%, Neutrophils 62%, Lymphocytes 26%; Eosinophils 12%; Platelet count 1.84 lakh/mm³. The Total Ig E testing was previously done on October 10, 2018, that reported IgE value 1293.3 iUA/L. The liver function, renal function and blood lipids levels were within normal limits. The UAS 7 score for the past week prior to admission was 42 and CU-Q20L was 103.

2.4. Clinical findings

Ayurvedic parameters assessed using AstasthanaPariksha (eightfold examination) were Nadi (pulse)-Sarpagati, Mutra (Urine)
The primary focus of Ayurveda is a personalized approach to Sheethapitta on the basis of age of the patient, degree of Dosha vitiation, duration of illness, the severity of of the disease and strength of the patient. The treatment outcome was evaluated using UAS 7 and the QoL was assessed using CU-Q2OL.

During the first visit the patient was requested to monitor hives and itching daily for one week using a validated weekly UAS7 and CU-Q2OL. The scores were 42 and 103 respectively suggestive of severe disease activity and poor QoL. Oral medication was administered during the first visit which led to slight improvement in the symptoms and QoL. Considering the chronic and non-responsive nature of patient’s condition to conventional treatment strategies and oral Ayurvedic medications, the primary focus was to detoxify and rejuvenate the body for disease cure and prevention of auto-immune responses, auto-allergy and mast cell activation. The patient was hospitalized for the administration of Vamana (therapeutic emesis) as itching and rashes were the predominant symptom. As a preparatory step for Vamana, Deepana-Pachana (therapeutic enhancement of digestive capacity), was conducted for 2 days with Vaisvanara Choorna (a powder formulation for improving digestive power). The patient reported lightness of the body, good appetite and sufficient energy levels after two days. It was followed by Snehapana (therapeutic administration of unctuous formulation like ghee, oil) with Mahathikthaka Ghṛtha (a medicated ghee preparation used in management of skin diseases) till the signs of oleation were observed. The signs of oleation were sticky bowel with the presence of ghee, soft and oily skin, aversion to ghee, nausea and tiredness. The complaints started to reduce from the 5th day of Snehapana and completely subsided after Vamana. The itching and hives subsided completely and the patient was then discharged with medicine prescription and was asked to monitor hives and itching daily for one week.

Re-admission was advised after 15 days for Sadayovirechana (therapeutic purgation without planned oleation and sudation) as Ayurveda advised repeated purificatory therapies in the management of chronic skin diseases. The patient visited OPD for the treatment after 28 days and reported a reoccurrence of symptoms which could be managed through administration of prescribed medications. He was re-hospitalized for Sadayovirechana for one day and discharged with oral medications. He was advised to monitor hives and itching daily for one week with UAS 7 score and to report them during follow-up after 15 days. The OPD and IPD interventions are enlisted in Table 2.
4. Follow-up and outcome

Soon after Vamana the UAS 7 score reduced to zero from the maximum score of 42 at the time of admission, which was increased to 4 after Virechana and reduced to zero after the follow-up (Supplementary file-Table 3). The patient remained in remission till 160 day follow-up. Over telephone, as reported by the patient there was no remission since past 30 months. Chronic Urticaria Quality of life score was assessed at the time of admission and after follow-up which was 103 and 31 respectively indicating significant improvement in the quality of life. On visual assessment the patient was found to have no signs of hives and wheals (Fig. 1e–h). The biochemical and haematological variables before and after different treatments were found to be normal which indicated the safety of the prescribed treatment (Supplementary file-Table 4).

5. Discussion

Considering the chronic and non-responsive nature of the disease to conventional management such as antihistamine therapy, AST and OMA, as well as oral Ayurvedic medications a deep-seated pathology was assumed to be associated with it. Considering the disease chronic and severe disease symptoms in-patient Panchakarma treatment-Vamana was administered after Sneha pana (administering oleaginous preparation through oral route) with Mahathikthaka Ghrtha. Vamana was carried out for eliminating the accumulated toxins that are kapha predominant and Mahathikthaka Ghrtha was selected as it is indicated in Kusta (a group of skin diseases) especially associated with Pitta predominance. Haridra khandha is given for prevention of recurrence as it is indicated in Seethapitta. It has Haridra (Curcuma longa L) as the main ingredient that has been proven to have anti-inflammatory and antiallergic properties by inhibiting Immunoglobulin E-mediated Mast Cells activation [19]. As the patient had allergic skin lesion with itching along with redish discolouration, the involvement of rakta was inferred. Manjistadi kwatha indicated for Rakta involvement and reddish discolouration. By virtue of ingredients it is a Thikthakashaya (bitter and astringent taste) predominant formulation that further prevents Kapha dosha aggravation. Arogyavardhini Vati advised in the treatment of skin diseases was administered along with it as it contains Katuki (Picrorhiza kurrooa Royle) which helps in maintaining mild laxation during the treatment.

Ayurveda advises frequent purificatory procedures to avert the recurrence of chronic skin maladies. So a Sadyovirechana was scheduled with Avipathy choorna which has Trivrit (Operculinaturpethum (L.) Silva Manso) as the main ingredient, mixed with decoction of Triphala. The combination is advised in the treatment of Visarpa (a type of skin disease) for purgation in all skin diseases [20]. As the patient is in remission during the follow up with an improvement in the Quality of life, Saribadyasava was also added to prevent any exacerbation due to hot weather as the formulation is also indicated in condition where Vata along with Rakta is vitiates. Also, Sariba (Hemidesmus indicus (L.) R. Br. ex Schult.) containing drugs are usually indicated in Ayurveda in skin diseases and conditions were Pitta dosha is involved. At present, the patient is under continuous observation and oral treatment. The quality of life of the patient has significantly improved. Till date (23/08/19), not only there is no exacerbation of symptoms in the patient but also the improvement in Quality of life was reported. There was also complete absence of adverse events reported during the course of treatment. This is an important finding with respect to the disease severity, prognosis, and non-response to established conventional therapies.

6. Conclusion

Panchakarma procedures along with oral medication are safe and effective in the management of CSU that is unresponsive to standard treatments including OMA injection. It can also prevent the recurrence of chronic diseases like CSU. Further studies with larger sample size in different settings are recommended for validation.
7. Patient perspective

The patient was very happy with the response he got from Ayurvedic panchakarma procedures in a short duration of time. Since 2018 he opted for different types of conventional treatments for the same with no significant relief. It was affecting his work and mood to the extent that he used to take frequent leave from his workplace. The treatment helped in gaining confidence, improve the quality of life and he was able to take almost all types of food. As reported by the patient he is asymptomatic since last 1 ½ years subsequent to treatment and happy with the outcome.

8. Patient consent

Written permission for publication of this case study had been obtained from the patient.

Source of funding

None.

Conflict of interest

None.

Authors contribution

Krishna Rao S: Managed the case and Prepared Original Draft. Indu S: Writing - Review & Editing, Methodology. A.K. Panda: Management of the case, Conceptualization and editing. Binitha P: Review & Editing. Bikash Ranjan Kar: Diagnosis, conceptualization and editing the manuscript.

Acknowledgements

We sincerely thank the Director, CARIHD, Bhubaneswar for his support and guidelines.

Appendix A. Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.jaim.2022.100549.

References

[1] Vestergaard C, Toubi E, Maurer M, Triggiani M, Ballmer-Weber B, Marsland A, et al. Treatment of chronic spontaneous urticaria with an inadequate response to H 1-antihistamines: an expert opinion. Eur J Dermatol 2017 Jan;27(1):10–9.
[2] Godse K, De A, Zawar V, Shah B, Girdhar M, Rajagopalan M, et al. Consensus statement for the diagnosis and treatment of urticaria: a 2017 update. Indian J Dermatol 2018 Jan;63(1):2.
[3] Zuberbier T, Maurer M. Omalizumab for the treatment of chronic urticaria. Expert Rev Clin Immunol 2015 Feb 1;11(2):171–80.
[4] Bindels-Jensen C, Skov PS. Efficacy of omalizumab in delayed pressure urticaria: a case report. Allergy 2010;65:138–9.
[5] Hollis K, Proctor C, McBride D, Bulp MM, McLeod L, Hunter S, et al. Comparison of urticaria activity score over 7 days (UA7) values obtained from once-daily and twice-daily versions: results from the ASSURE-CSU study. Am J Clin Dermatol 2018 Apr;19(2):267–74.
[6] Dias GA, Pires GV, Vello SO, Dortas Júnior SD, Levy S, França AT, et al. Impact of chronic urticaria on the quality of life of patients followed up at a university hospital. An Bras Dermatol 2016 Dec;91(6):754–9.
[7] Upadhyaya Y, MadHAVanandana of Sri MadHAVakara. Chapter 57, Verse 1–3. 17th ed. Varanasi: Chaukhambha Sanskrit Sansthan; 1987. p. 290.
[8] Tripathi B, Charaka Samhita of Agnivesa, Sutthra Sthana; Atreyadhikapakya Adhyaya. Chapter 29, Verse 81. Varanasi: Chaukhambha Bharati Academy; 2007. p. 492.
[9] Chaturvedi A, Rao PN, Kumar MA, Ravishankar B, Rao N, Ravi M. Effect and mechanism of Virechana Karma (Therapeutic Purgation) over fructose-induced metabolic syndrome: an experimental study. J Evid Based Complementary Altern Med 2016 Jul;21(3):194–201.
[10] Ambikadatta Shastri. Rasaratna Samuchchya chapter 20. Verse 87. 9th ed. Varanasi: Chaukhambha Sanskrit sansthan; 1999. p. 851.
[11] Sharma P, Dravyaguna sutram; Aushadha prakarana, Chapter 8, Verse 9. Varanasi: Chaukhambha Sanskrit sansthan; 2009. reprint.
[12] Singh RH. Charak Samhita of Agnivesha. 1st ed. Vol. 2. Varanasi: Chaukhambha Surabharati Prakashan; 2011. p. 1042. reprint.
[13] Sreekantamurthy KR. Astagahridaya of Vagbhata, Chikitsa. chapter 14, Volume 2, Verse 34. 5th ed. Chaukhambha Suhbharati PrakasanVaranasi; 2003. p. 406.
[14] Sreekantamurthy KR. Astagahridaya of Vagbhata, Chikitsa. chapter 15, Volume 2, Verse 8–11. 5th ed. Chaukhambha Suhbharati PrakasanVaranasi; 2003. p. 473.
[15] Sastri KA. Commentary on Bhaishajya Ratnavali of Govinda Das. 16th ed. Varanasi: Chaukhambha publication; 2002. p. 641.
[16] Vaidyan Krishnana KV, Pillai Gopala S. Commentary Sujanapriya, Choorna Prakaranam. 24th ed. November. Visvarambhann Publications; 2002. p. 165.
[17] Pandey G, editor. Bhaishajya Ratnavali of Govinda Das. Prameha pidaka adhikara, Chapter 52, Verse 5. Varanasi: Chaukhambha Sanskrit series; 2008. p. 702.
[18] Li X, Lu Y, Jin Y, Son JK, Lee SH, Chang HW. Curcumin inhibits the activation of immunoglobulin e-mediated mast cells and passive systemic anaphylaxis in mice by reducing serum eicosanoid and histamine levels. Biomol Ther 2014;22(1):27.
[19] Sreekantamurthy KR. Astagahridaya of Vagbhata, Chikitsa. chapter 18, Volume 2, Verse 3–4. 5th ed. Chaukhambha Surbharati PrakasanVaranasi; 2003. p. 465.